Sanofi-Synthelabo India, the local subsidiary of the euro 6.5 billion French pharmaceuticals major Sanofi-Synthelabo, has chalked out a major expansion plan, which involves the buyout of domestic brands, the launch atleast ten new products in the next 12-36 months, and investments in distribution and manpower.
